| Date | Time | Source | Headline | Symbol | Company |
| 05/17/2024 | 3:00PM | iHub Newswire | FeaturedMusic Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements | | |
| 05/15/2024 | 4:30PM | GlobeNewswire Inc. | Elevai Labs Inc. Reports First Quarter 2024 Financial Results | NASDAQ:ELAB | Elevai Labs Inc |
| 05/15/2024 | 4:02PM | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:ELAB | Elevai Labs Inc |
| 05/09/2024 | 4:01PM | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:ELAB | Elevai Labs Inc |
| 05/02/2024 | 8:30AM | GlobeNewswire Inc. | Elevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of Obesity | NASDAQ:ELAB | Elevai Labs Inc |
| 05/01/2024 | 4:00PM | GlobeNewswire Inc. | Elevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome Skincare | NASDAQ:ELAB | Elevai Labs Inc |
| 05/01/2024 | 9:00AM | GlobeNewswire Inc. | Elevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity Treatments | NASDAQ:ELAB | Elevai Labs Inc |
| 04/29/2024 | 9:45AM | GlobeNewswire Inc. | Elevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue Commitments | NASDAQ:ELAB | Elevai Labs Inc |
| 04/22/2024 | 8:00AM | GlobeNewswire Inc. | ELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 Months | NASDAQ:ELAB | Elevai Labs Inc |
| 03/29/2024 | 12:00PM | GlobeNewswire Inc. | Elevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial Results | NASDAQ:ELAB | Elevai Labs Inc |
| 03/18/2024 | 8:51AM | InvestorsHub NewsWire | Elevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical Market | NASDAQ:ELAB | Elevai Labs Inc |
| 01/24/2024 | 8:30AM | GlobeNewswire Inc. | ELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark Office | NASDAQ:ELAB | Elevai Labs Inc |
| 01/17/2024 | 9:07AM | InvestorsHub NewsWire | ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach | NASDAQ:ELAB | Elevai Labs Inc |
| 01/17/2024 | 8:30AM | GlobeNewswire Inc. | ELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global Reach | NASDAQ:ELAB | Elevai Labs Inc |
| 01/16/2024 | 10:05AM | InvestorsHub NewsWire | ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology | NASDAQ:ELAB | Elevai Labs Inc |
| 01/16/2024 | 8:30AM | GlobeNewswire Inc. | ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing Technology | NASDAQ:ELAB | Elevai Labs Inc |
| 01/02/2024 | 9:15AM | GlobeNewswire Inc. | ELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry Conferences | NASDAQ:ELAB | Elevai Labs Inc |
| 12/11/2023 | 9:15AM | GlobeNewswire Inc. | Elevai Labs Inc Announces Financial Results for the Quarter Ended September 30, 2023 | NASDAQ:ELAB | Elevai Labs Inc |
| 12/07/2023 | 9:41AM | GlobeNewswire Inc. | ELEVAI Labs, Inc. Expands International Distribution into Europe | NASDAQ:ELAB | Elevai Labs Inc |
| 11/29/2023 | 9:00AM | GlobeNewswire Inc. | Elevai Labs Enters into Licensing Agreement with Yuva Biosciences to Combine Exosome and Mitochondrial Technologies to Develop New Aesthetics Products | NASDAQ:ELAB | Elevai Labs Inc |
| 11/24/2023 | 1:38PM | PR Newswire (US) | ELEVAI Labs, Inc. Announces Closing of $6,000,000 Initial Public Offering | NASDAQ:ELAB | Elevai Labs Inc |
| 11/24/2023 | 12:00PM | GlobeNewswire Inc. | Univest Securities, LLC Announces Closing of $6 Million Initial Public Offering of Common Stock for its Client ELEVAI Labs Inc. (Nasdaq: ELAB) | NASDAQ:ELAB | Elevai Labs Inc |
| 06/23/2005 | 5:13PM | Business Wire | Eon Labs Receives Final Approval for Bupropion HCl, ER 200mg Tablets and Will Begin Shipping Immediately | NASDAQ:ELAB | Elevai Labs Inc |
| 06/13/2005 | 5:41PM | Business Wire | Appeals Court Affirms that Eon Labs' Itraconazole Does Not Infringe Janssen's Patent | NASDAQ:ELAB | Elevai Labs Inc |